PCOS Has a New Name. And It's Long Overdue.

If you have PCOS, or suspect you might, you may have seen the news. On 12 May 2026, a landmark paper published in The Lancet officially renamed polycystic ovary syndrome to polyendocrine metabolic ovarian syndrome. PCOS is now PMOS.

One letter different. But the reasoning behind it matters, and I want to explain why, because if you have spent years being told confusing, contradictory, or frankly inadequate things about this condition, this change goes some way toward explaining why that happened.

🧠 So what was wrong with the old name?

Quite a lot, as it turns out.

Polycystic ovary syndrome implies that the defining feature of the condition is cysts on the ovaries. The problem is that those aren't actually pathological cysts. What shows up on an ultrasound are small, immature follicles that haven't developed properly - not cysts in any clinical sense. And to make it more confusing, many women with PCOS don't even have those on their scans at all, yet still have every other feature of the condition.

So for decades, women were told "you can't have PCOS because your ovaries look normal," while experiencing insulin resistance, irregular periods, acne, unwanted hair growth, fatigue, weight difficulties, anxiety, and a cluster of other symptoms that were all very much part of the picture. They were sent away without answers because the name of the condition didn't match what the doctor was looking at.

The Lancet paper is direct about this. The inaccurate name contributed to delayed diagnosis, fragmented care, and stigma, while curtailing research and policy framing. The condition was being treated as a gynaecological problem, when in reality it is a complex, multi-system condition involving hormones, metabolism, the cardiovascular system, mental health, and the reproductive system too. The name was only telling part of the story, and a misleading part at that.

What PMOS actually means

Let's break the new name down:

Polyendocrine means multiple hormonal systems are involved. It's not just a problem with the ovaries producing too many androgens. The adrenal glands, the pituitary gland, and insulin signalling all play a role. This is a hormonal condition in the fullest sense, and the new name says so.

Metabolic acknowledges what has been consistently overlooked in clinical practice: that insulin resistance is central to PMOS for the majority of women who have it, and that the associated risks including type 2 diabetes and cardiovascular disease are a serious and underaddressed part of the picture. Women weren't just being under-diagnosed. They were being under-treated, because the metabolic complexity of the condition wasn't reflected in what it was called.

Ovarian is retained because the ovaries remain genuinely relevant. Abnormalities in follicle development and ovulation are key features. The ovaries are involved - they're just not the whole story, and they're not full of cysts.

Syndrome correctly reflects that this is a cluster of features rather than a single cause, which is why two women with PMOS can look and feel different from each other.

What it actually looks and feels like

PMOS typically begins at puberty under the age of 18 and can women right through until menopause, meaning it can shape a significant portion of someone's life.

The main symptoms include: 

• irregular periods or long gaps between cycles

• excessive hair growth (hirsutism) or hair loss

• weight gain or difficulty losing weight despite genuine effort

• difficulty getting pregnant

• persistent fatigue

• oily skin and acne

• thick dark patches of skin on the neck or armpits (acanthosis nigricans)

• Mental health difficulties including depression and anxiety

  
  

PMOS doesn't just originate in the ovaries - it originates in the brain. Disrupted signalling from the hypothalamus triggers imbalances across insulin, androgens like testosterone, and neurotransmitters including dopamine and serotonin. This is why the condition affects not just hormones and fertility, but how you think, feel, and function day to day.

The brain fog, poor concentration, and anxiety that so many women with PMOS describe aren't incidental. Fluctuating insulin and androgens disrupt dopamine pathways, which helps explain the significant overlap with ADHD. Inconsistent progesterone disrupts the brain's GABA system, its primary calming mechanism, which is why anxiety and irritability so often worsen before a period. And chronic low-grade inflammation compounds the fatigue and low mood that can make PMOS feel relentless.

🔬 How this name came about

This wasn't a quick rebrand. The rename followed more than a decade of vigorous debate and involved responses from 22,000 people over 11 years. More than 56 patient and professional organisations worldwide were involved, including the Endocrine Society and the American Society for Reproductive Medicine. Women with lived experience of the condition were, by all accounts, the biggest drivers of the change.

It is one of the most thoroughly consulted disease renamings in medical history. Which is either reassuring or slightly depressing depending on how you feel about how long it took!

What this means in practice

The condition remains underdiagnosed in up to 70% of affected patients. A more accurate name should in theory, help clinicians recognise it earlier and more consistently, and help patients feel that what they are experiencing is being properly seen rather than reduced to a scan result.

It should also shift the conversation away from the ovaries and toward the big picture, which means insulin resistance, inflammation, mental health, and long-term metabolic risk all need to be part of what gets assessed and addressed. Not just periods and fertility, which is what many women have historically had their appointments reduced to. This matters beyond the reproductive years too - as insulin resistance and chronic inflammation, both central features of PMOS, are increasingly linked to long-term cognitive decline, including Alzheimer's disease. Getting on top of the metabolic side of this condition earlier is not just about managing symptoms now. It is about protecting your brain health for the decades ahead. 

There is a three-year transition period, so you will see both PCOS and PMOS used interchangeably for a while. Your diagnosis doesn't change, your symptoms don't change, and your treatment doesn't change overnight - but the framework around how this condition is understood, and therefore how it is managed, should gradually improve.

🌱 What hasn't changed: nutrition is still central

As someone who works with a lot of women with PMOS, and who has written about this in depth before, I want to be clear that the most effective nutritional strategies remain exactly what they were. Blood sugar stability, addressing insulin resistance, reducing inflammation, supporting gut health, and filling the specific nutrient gaps that PMOS creates are all still the foundation of what I do with my clients in this space. And increasingly, I work with women on the longer-term brain health picture too, including cognitive decline and Alzheimer's prevention, where the metabolic and hormonal roots of PMOS are very much part of the conversation. 

If anything, the new name validates the approach I have always taken. PMOS is a metabolic and endocrine condition first. Food is one of the most powerful tools you have to influence both of those things, and that isn't changing.

If you have PMOS and you have never had proper support around nutrition and the metabolic side of your condition, I would genuinely love to help. Because "eat less and exercise more" has rarely ever been a sufficient answer, and with a name that finally reflects what this condition actually is, perhaps it will be easier to make the case for the kind of thorough, personalised care you deserve.

Click here to book a chat.